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INTRODUCTION Background
Febrile neutropenia is a well-known complication of chemotherapy and is one of the more common oncologic emergencies encountered by emergency physicians. 1 Despite advances in chemotherapeutic agents and prophylactic therapies, the prevalence of this disease is unlikely to decrease significantly in the foreseeable future. 2 Although the acute care of febrile neutropenic patients may vary across institutions, it has historically been considered an inpatient condition that requires broad-spectrum antibiotics and observation until fever and neutropenia resolve. There is a growing body of oncologic research, however, that suggests that such an aggressive, hospitalbased therapeutic strategy may be unnecessary for a specific subset of low-risk febrile neutropenic patients. 3, 4 Several risk-stratification tools have been suggested to help identify patients with febrile neutropenia who may be appropriate for outpatient management. 5, 6 These models use multivariate logistic regression to identify several clinical and laboratory characteristics that combine to form an overall risk-stratification tool. In 1988, the Talcott score was created as one of the first validated and widely adopted decision rules used to identify this low-risk cohort. 7 This
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Editor's Capsule Summary
What is already known on this topic Although patients with chemotherapy-induced febrile neutropenia are at high risk of infection, some patients can be managed as outpatients.
What question this study addressed How well do the Multinational Association for Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores identify emergency department (ED) patients who are at low risk for adverse events?
What this study adds to our knowledge In this retrospective study of 230 patients, the 3-level CISNE score identified 23% as low risk, with specificity 98% (95% confidence interval 89% to 100%), whereas the 2-level MASCC score identified 73% as low risk, with specificity 54% (95% confidence interval 41% to 67%).
How this is relevant to clinical practice
Prospective studies are warranted before either score can be used to guide ED disposition in chemotherapy-induced febrile neutropenia patients.
was followed in 2000 by the Multinational Association for Supportive Care in Cancer (MASCC) score, which was presented as a more sensitive test, with similar specificity and less misclassification than previous decision rules. 8, 9 Finally, the Clinical Index of Stable Febrile Neutropenia (CISNE) score was published in 2015 and reported increased specificity and positive predictive value in the identification of low-risk febrile neutropenic patients. 10 Additional studies have demonstrated that these low-risk patients can be safely managed in the outpatient setting with broad-spectrum oral antibiotics and close clinical follow-up. 11, 12 This management strategy not only shields these patients from exposure to multidrug-resistant nosocomial infections but also avoids unnecessary, costly admissions. 13 Unfortunately, all of the previous riskstratification tools have focused on the clinic and inpatient hospital settings. None of these decision rules have been validated or specifically designed for use in the emergency department (ED) setting.
Importance
Among the few studies that have investigated the safety and feasibility of discharging low-risk febrile neutropenic patients from the ED, none have used a standardized, validated, riskstratification tool. [13] [14] [15] [16] The inclusion and exclusion criteria among these investigations vary widely. In general, however, these preliminary studies have shown that patients with low symptom burden and few comorbidities may be safely discharged with oral antibiotics and close clinical follow-up.
Goals of This Investigation
We designed this study to investigate whether the MASCC and CISNE scores could be applied in the ED setting to appropriately identify low-risk febrile neutropenic patients.
MATERIALS AND METHODS Study Design and Setting
We conducted a retrospective cohort study to evaluate all patients with chemotherapy-induced febrile neutropenia who presented to 2 academic EDs from June 2012 through January 2015.
Selection of Participants
An electronic medical records system was used to identify study subjects with the admission or discharge diagnoses of "febrile neutropenia," "fever and neutropenia," "neutropenia," "neutropenia with fever," "neutropenic," or "neutropenic fever." All identified charts were then evaluated by 2 investigators (C.J.C. and V.L.) to ensure that study subjects met predetermined inclusion and exclusion criteria. These abstractors were unaware which score was expected to perform better. Patients were included if they were aged 16 years or older, if they had a documented fever at home or in the ED (38 C [100. 4 F]), and if their absolute neutrophil count (ANC) was less than 1,000 cells/mL. Patients were excluded if their neutropenia was considered unrelated to chemotherapy.
Methods of Measurement
A standardized data collection tool was used to abstract predictor and outcome data, and each chart abstractor underwent training to limit confusion and to increase precision in data collection. Monthly research meetings were conducted to answer questions and to ensure adherence to study protocols. Other methods to limit bias were used, as instructed in the article on retrospective reviews by Kaji et al. 17 These methods included blinding of study abstractors to the study hypothesis, defining a priori our predictor and outcome variables, pilot testing our study instrument, performing a sample size calculation, and performing a measurement of interrater reliability.
The index visit for each included patient was evaluated for several characteristics, including age, sex, degree of neutropenia, disposition from the ED, and type of cancer, as well as those characteristics on the MASCC and CISNE scores ( Figure 1 ). Liquid malignancy (cancer of the blood or bone marrow) and solid malignancy (eg, cancers of the lung, breast, prostate, colon rectum, bladder) underwent planned secondary analyses to compare outcomes. We also performed planned secondary analyses to assess for outcome differences between different grades of neutropenia. In calculating the MASCC score, symptom assessment was based on the ED provider note, as well as any ED provider progress notes during the course of treatment. Mild symptoms were generally considered events barely noticeable and not interfering with performance or functioning (eg, mild pain, chills, myalgias, arthralgias, rhinorrhea, mild nausea). Moderate symptoms were those that made the patient uncomfortable and had a negative influence on the performance of daily activities. Severe symptoms were those that caused severe discomfort or severely limited functioning and the performance of daily activities.
In calculating the CISNE score, the Eastern Cooperative Oncology Group performance status was ascertained with electronic notes from the most recent oncology clinic visit (within 2 weeks) for each patient, relative to the index ED visit. This score describes a patient's general functional status, ranging from fully active (1), to limited self-care (3), to death (5) . If the Eastern Cooperative Oncology Group score was not documented, each reviewer would assign the score according to ED documentation and recent oncology office visits. The presence and grade of mucositis were ascertained with the National Cancer Institute (NCI) mucositis grading scale and the documented findings in ED provider notes and the initial inpatient history and physical note (if the patient was admitted). If the review of symptoms and physical examination did not indicate any mouth pain or oral lesions, then the patient was not considered to have mucositis. Elements of the score that referred to preexisting conditions, including chronic obstructive pulmonary disease and chronic cardiovascular disease, were assessed through an investigation of the patient's documented medical history, his or her active problem list, the ED provider note, and the inpatient history and physical examination result. A determination of All pa ents with fever (temp ≥38°C or 100.4°F) and neutropenia (ANC<1000) n=247
17 pa ents excluded because febrile neutropenia was not chemotherapy related 230 pa ent charts reviewed to apply risk score and measure outcome variables Figure 1 . Plot of patient enrollment and risk stratification using CISNE and MASCC scoring. ECOG PS, Eastern Cooperative Oncology Group performance score; SBP, systolic blood pressure; SIH, stress-induced hyperglycemia; COPD, chronic obstructive pulmonary disease; CVD, chronic cardiovascular disease. *Stress-induced hyperglycemia: initial blood glucose level 121 mg/dL or 250 mg/dL if patient has history of diabetes mellitus or if patient is receiving steroids.
† COPD with the use of steroids, supplemental oxygen, or bronchodilators.
‡ Excluding single uncomplicated episode of atrial fibrillation in the past. § At least the presence of patchy ulcerations or pseudomembranes, or moderate pain with modified diet indicated. chronic cardiovascular disease excluded hypertension and a single, uncomplicated episode of atrial fibrillation. We defined "uncomplicated" as an episode of atrial fibrillation that did not result in hypotension and was not refractory to treatment. The episode had to be brief and must have resolved before hospital discharge. In situations in which calculated MASCC and CISNE risk-stratification levels between the 2 reviewers were incongruent, a third reviewer (R.A.S.) would arbitrate and determine the final level.
To appropriately compare CISNE and MASCC risk stratification, there was a change in the exclusion method used for the CISNE score. As noted in Figure 1 , patients who had evidence of acute organ failure, severe infection, hypotension, or another reason for admission were automatically considered high risk. In the original CISNE derivation, this group was excluded from analysis (although this group would have been included in MASCC). This change in protocol allowed an equal distribution of disease burden in patients being evaluated by each score (as opposed to no CISNE evaluation and scoring for the most critically ill patients).
Outcome Measures
For all admitted patients, several outcome variables were also recorded according to the index hospital stay, including inpatient length of stay, upgrade in level of care, clinical deterioration, positive blood culture results, and death. Clinical deterioration was defined as acute organ failure (laboratory or clinical evidence of acute renal failure, liver failure, heart failure, or respiratory failure), altered mental status, hypotension, or other disease process that necessitated an acute change in clinical management. Clinical signs of renal, liver, or heart failure included newonset or worsening peripheral edema, ascites, pulmonary edema, dyspnea, or increased supplemental oxygen demand. For discharged patients, notes from subsequent visits up to 30 days postdischarge were reviewed to evaluate for adverse outcomes. We define true low risk as patients who did not experience any of these negative outcomes.
Primary Data Analysis
All data were analyzed with IBM SPSS (version 21; IBM, Armonk, NY). Descriptive statistics were reported for all outcome variables. Continuous variables were analyzed with Wilcoxon rank sum. A sample size of 218 was determined as adequate, assuming a confidence level of 95%, 80% power, and a risk:prevalence ratio of 5. A Cohen's k value was calculated to assess for interrater agreement in the determination of low risk for both the MASCC and CISNE scores. We conducted our interrater reliability assessment on a 10% random sample of study enrollments.
This study was reviewed and certified by the university institutional review board.
RESULTS
Characteristics of Study Subjects
We identified 247 ED visits for febrile neutropenia from June 2012 through January 2015. There were 17 patients excluded from this group because their neutropenia was found to be unrelated to chemotherapy (16 from myelodysplastic syndrome and 1 from HIV/AIDS). Therefore, 230 patients were included in our final analysis (Figure 1 ). The mean age of our study population was 55 years (range 21 to 86 years), and approximately 49% (n¼113) of the patients were men. A majority of this population had severe neutropenia (ANC<500; 82.6%; n¼190) and liquid malignancy (65.7%; n¼151). Most patients were considered to have mild symptoms (85.2%; n¼196) and most were admitted to an unmonitored setting (medical/surgical; 80.9%; n¼186). Among all patients, 25.7% (n¼59) experienced at least one negative outcome, with bacteremia being the most common one (16.5%; n¼38) ( Table 1) . Only 4 patients were discharged from the ED. These patients were followed for 30 days postdischarge and none had a negative event.
Main Results
Among all outcome variables, the CISNE score was highly specific in the identification of a low-risk cohort, which represented 23% (n¼53) of the included patients. The score was 100% specific in the identification of low risk for all outcome variables except bacteremia, for which the score was 97.4% specific (95% confidence interval [CI] 84.6% to 99.9%) (one positive blood culture result in the low-risk group). The positive predictive value of the CISNE score in the identification of low-risk patients was 98.1% (95% CI 88.6% to 99.9%) for our pooled outcome variable (any negative outcome).
The MASCC score was much less specific in the identification of a low-risk cohort for all outcome variables (54.2%; 95% CI 40.8% to 67.1%) for any negative outcome versus 98.3% for the CISNE score. The prevalence of positive blood culture results in the low-risk MASCC group was particularly high (13.8%; n¼20). Tables 2 through 5 demonstrate the performance of each score in the prediction of a high-and low-risk cohort. Figure 2 demonstrates the performance of the MASCC score as the low-risk cutoff is varied from 21 to 26. To approach a sensitivity of 100% in the identification of a high-risk cohort, it was necessary to set the MASCC low-risk cutoff to 26, which decreased the corresponding specificity to 6%. Figure 3 demonstrates the distribution of negative outcomes based on CISNE and MASCC risk categorization.
These data were further subdivided in Figure 4 to show the effect of severe neutropenia and cancer type on outcomes. Lower neutrophil counts, as well as hematologic malignancy (liquid), were associated with increased incidence of negative outcome across all risk categories. The single adverse event in the low-risk CISNE group occurred in a patient with acute myeloid leukemia with severe neutropenia. Table 6 demonstrates that increasing risk categorization correlates with increased hospital time. Specifically, lowrisk CISNE patients stayed a median of 3 days in the hospital compared with 6 days for high-risk CISNE patients (P<.001).
Our assessment of interrater agreement resulted in a k of 0.77 (95% CI 0.58 to 0.96) for the CISNE score risk stratification and a k of 0.65 (95% CI 0.41 to 0.89) for the MASCC score risk stratification. Both of these scores represent substantial agreement, according to Landis and Koch. 18 
LIMITATIONS
This study involved several limitations. Because it was a retrospective study based on chart review, there is potential for misclassification bias, particularly in relation to patient symptoms. Although each chart was reviewed at length, with a particular assessment of symptom burden defined a priori, this was ultimately secondhand data recorded by the treating physician. If each patient had been asked directly, he or she may have reported an increased or decreased symptom burden. This information may have altered the calculation of the MASCC score; however, the CISNE score would remain unchanged (no symptom-based criteria). Given that the majority of patients had "mild" symptoms in our study, we suggest that a corrected symptom score would likely move patients into higher symptom brackets and thus decrease their MASCC risk assessment score. This would improve the risk-stratification tool by moving those patients erroneously placed in the low-risk cohort into the high-risk group. In regard to missing data, there were 6 patients who did not have a documented Eastern Cooperative Oncology Group score. Per our protocol, these scores were calculated by study investigators using information available in ED documentation and recent office visits. These data were limited, however, and may not reflect the actual patient Eastern Cooperative Oncology Group scores. If symptoms and physical examination findings pertinent to the MASCC and CISNE scores were not documented in ED notes (eg, mucositis), then these conditions were considered absent. This may not represent the actual patient condition, and may only reflect lack of documentation. There were no missing laboratory or vital sign data.
In reference to the external validity of this study, the enrollment sites were both associated with a National Institutes of Health-designated cancer center. This likely increases the prevalence of disease in our study relative to that in general community EDs. We suggest, however, that as the prevalence of disease decreases when one moves away from these academic centers, the positive predictive value of the CISNE score in the detection of a low-risk cohort should appropriately increase, and thus the performance of the score should improve.
To appropriately compare CISNE and MASCC risk stratification, there was a change in the exclusion method used for the CISNE score. Instead of excluding patients who had evidence of acute organ failure, severe infection, hypotension, or another reason for admission, we placed them into the high-risk CISNE category. This change in protocol increased the prevalence of disease in our cohort, although it did not affect the ultimate disposition of these high-risk patients (all would be admitted).
DISCUSSION
Through this retrospective cohort study on febrile neutropenic patients, we have identified the CISNE score as a highly specific tool in the identification of a low-risk cohort of ED patients. Previous literature has identified similar differences in test characteristics between the CISNE and MASCC scores, with the CISNE score outperforming the MASCC score in the correct identification of a low-risk cohort. 10 In the ED, one of our most difficult tasks is deciding who is at the greatest risk of decompensating and who is safe to be treated at home. Each of these scores previously demonstrated the ability to appropriately risk-stratify a clinic and inpatient population, although neither has been validated in the ED setting. This study is the first step toward establishing validated criteria for the discharge of low-risk febrile neutropenic patients directly from the ED.
The results of this study suggest that the CISNE score, when applied to patients in the ED, can accurately predict which patients are at the lowest risk of complications while being treated in the hospital with intravenous antibiotics. The question remains whether these findings can be extrapolated to discharged patients who are being treated with broad-spectrum oral antibiotics. There are previous data that suggest oral antibiotics can be safely and effectively used for patients with low-risk febrile Table 4 . Descriptive statistics for CISNE or MASCC identification of low risk for the outcome: any negative outcome (one or more negative outcomes). PPV, Positive predictive value; NPV, negative predictive value; þLR, positive likelihood ratio; -LR, negative likelihood ratio. Table 5 . Descriptive statistics for CISNE or MASCC identification of high risk for the outcome: any negative outcome (one or more negative outcomes). neutropenia. 19 In a randomized multicenter trial by Kern et al 20 that randomized febrile neutropenic patients to either ceftriaxone/amikacin or ciprofloxacin/amoxicillin clavulanate, there were no significant differences between treatment regimens in length of stay, duration of fever, duration of therapy, rate of complication, and survival. Similarly, a Cochrane review in 2013 that included 22 randomized controlled trials and 3,142 episodes of febrile neutropenia found that oral antibiotics were an acceptable treatment for low-risk patients. 21 The results of our investigation, coupled with these data, suggest that patients identified as low risk in the ED may be safely discharged from the ED with oral antibiotics and close follow-up. We acknowledge, however, that this is a single study and that further prospective trials may be necessary to provide additional evidence before this practice becomes standard of care.
Further considerations that must be explored include the duration of ED observation for low-risk patients, as well as the appropriate follow-up interval once they are discharged. Although the median length of stay for the low-risk CISNE patients in our study was 3 days, this was likely due to the ongoing inpatient practice of waiting for ANC recovery and initial blood culture results before patient discharge. 22 One may suggest that a prolonged hospital or observation stay is appropriate, although an alternative argument can be made for the expedited discharge of low-risk patients. 23, 24 This strategy may aid in the prevention of nosocomial infections.
The original CISNE derivation did not include patients with hematologic malignancies, nor did it include patients who were undergoing "intense" chemotherapeutic regimens. Although we did see a trend toward increased negative outcomes in the CISNE 2 and CISNE 3 groups among hematologic malignancy, there was no significant difference in outcomes between hematologic and solid malignancy among the CISNE 1 group. Given the performance demonstrated in this study, and the superior risk-stratification ability compared with the MASCC score (which was validated in both solid and liquid malignancies), we suggest that the CISNE score may be appropriately applied to hematologic malignancies. We chose to evaluate the CISNE score among all chemotherapeutic regimens, given that this score would be applied by emergency physicians who may not be aware of the "intensity" of certain chemotherapeutic agents, especially as newer agents are released. Regardless, in most cases there should be a discussion between the treating emergency physician and the patient's primary oncologist before discharge to decide the best course of action and to arrange for appropriate follow-up. This conversation may involve more subtle details of therapy and may help improve risk-stratification efforts.
An additional notable study characteristic involves the established definition neutropenia. Although the definition of moderate neutropenia is an ANC less than 1,000, previous risk-stratification studies have generally included only patients with an ANC less than 500, or an ANC less than 1,000 if expected to decrease below 500. As one can see in Figure 4 , however, there were several negative outcomes that occurred among patients in the moderate and high CISNE risk groups who maintained an ANC between 500 and 1,000. We therefore suggest that in patients with moderate neutropenia and fever, it is appropriate to apply CISNE risk stratification.
Several previous studies have suggested modifying riskstratification cutoffs to improve sensitivity or specificity. 10, 25 Raising the MASCC score low-risk cutoff may improve the sensitivity in the detection of high-risk febrile neutropenia. When we raised our low-risk MASCC cutoff to approach a sensitivity similar to that of the CISNE score in the identification of a high-risk cohort, however, we encountered a very low specificity, which may limit the usefulness of this strategy (Figure 2 ). Using the CISNE score moderate-risk category instead of using the score as a binary tool (low risk or "not low risk") may allow a third management strategy. This group may be appropriate for an expedited inpatient stay, or perhaps a prolonged observation stay in the ED. These are questions that we hope to actively investigate in future studies at our institution.
In summary, febrile neutropenia has been extensively studied by oncologists in the clinic and inpatient settings, whereas data are lacking on how to appropriately approach this disease in the ED. Among the 2 validated riskstratification tools commonly used by oncologists today, the CISNE score appears to outperform the MASCC score in the identification of low-risk febrile neutropenic patients presenting to the ED. Although the MASCC score does not appear to appropriately risk stratify febrile neutropenic patients in this setting, regardless of where one sets the lowrisk cutoff, the CISNE score does appear to be highly specific in the identification of a low-risk cohort. We suggest that patients with a CISNE score of zero, especially those with a solid tumor, can be safely discharged from the ED, assuming that they have access to expedited oncology follow-up. We hope to strengthen this recommendation with future prospective, randomized clinical trials investigating the CISNE score and its use in the ED for the risk stratification of febrile neutropenic patients. Author contributions: CJC, RAS, and GMV conceived of the study. CJC and VL completed the chart abstraction, with RAS as arbitrator. JJB and EMC provided statistical advice CJC drafted the article. SB and KF contributed substantial statistical and methodological advice during article revision. CJC takes responsibility for the paper as a whole.
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